Scholarlink

Background <p>Myopia presents a noteworthy global health concern, urging exploration of innovative treatments. The role of intraocular pressure (IOP) in regulating the progression of myopia has been controversial.</p> Methods <p>To investigate the impact of reducing IOP to varying extents on myopia progression, three groups receiving distinct IOP-lowering medications (Brinzolamide, Latanoprost, and a combination of Brinzolamide and Latanoprost) were designed in a form-deprived myopic guinea pig model. Additionally, proteomics analyses were conducted to identify differentially expressed proteins in the sclera.</p> Results <p>Based on 24-h and 4-week IOP monitoring, the group receiving both Brinzolamide and Latanoprost exhibited the greatest magnitude of IOP reduction and the most significant inhibition of axial length (AL) growth. Moreover, the administration of IOP-lowering medications increased choroidal thickness and induced alterations in the structure of scleral collagen fibrils. Notably, scleral proteomics revealed remodeling processes associated with key mechanisms, including proteolysis, fibrinolysis, and metal ion binding.</p> Conclusions <p>Our findings highlight that pressure-dependent scleral remodeling contributes to the deceleration of AL elongation. These results underscore the efficacy of IOP reduction in mitigating the progression of myopia, providing a promising alternative strategy for myopia management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intraocular pressure is a promising target for myopia control

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Peiyuan Wang,
  • Kangjie Kong,
  • Jiaxuan Jiang,
  • Jingwen Jiang,
  • Zihong Xie,
  • Fengbin Lin,
  • Yunhe Song,
  • Xiuli Fang,
  • Ling Jin,
  • Fei Li,
  • Wei Wang,
  • Shaolin Du,
  • Zhuoxing Shi,
  • Junwen Zeng,
  • Xiulan Zhang,
  • Shida Chen,
  • Xiulan Zhang,
  • Yizhi Liu,
  • Lin Lv,
  • David S. Friedman,
  • Jost B. Jonas,
  • Tin Aung,
  • Shida Chen,
  • Wei Wang,
  • Fengbin Lin,
  • Yunhe Song,
  • Peiyuan Wang,
  • Fei Li,
  • Kai Gao,
  • Bingqian Liu,
  • Yuhong Liu,
  • Meiling Chen,
  • Neil M. Bressler,
  • Ki Ho Park,
  • Dennis S. C. Lam,
  • Mingguang He,
  • Kyoko Ohno-Matsui,
  • Robert N. Weinreb,
  • Ching-Yu Cheng,
  • Paul Healey,
  • Linda M. Zangwill,
  • Xiang Chen Guangxian Tang,
  • Ling Jin

摘要

Background

Myopia presents a noteworthy global health concern, urging exploration of innovative treatments. The role of intraocular pressure (IOP) in regulating the progression of myopia has been controversial.

Methods

To investigate the impact of reducing IOP to varying extents on myopia progression, three groups receiving distinct IOP-lowering medications (Brinzolamide, Latanoprost, and a combination of Brinzolamide and Latanoprost) were designed in a form-deprived myopic guinea pig model. Additionally, proteomics analyses were conducted to identify differentially expressed proteins in the sclera.

Results

Based on 24-h and 4-week IOP monitoring, the group receiving both Brinzolamide and Latanoprost exhibited the greatest magnitude of IOP reduction and the most significant inhibition of axial length (AL) growth. Moreover, the administration of IOP-lowering medications increased choroidal thickness and induced alterations in the structure of scleral collagen fibrils. Notably, scleral proteomics revealed remodeling processes associated with key mechanisms, including proteolysis, fibrinolysis, and metal ion binding.

Conclusions

Our findings highlight that pressure-dependent scleral remodeling contributes to the deceleration of AL elongation. These results underscore the efficacy of IOP reduction in mitigating the progression of myopia, providing a promising alternative strategy for myopia management.